PY30 Stock Overview
Operates as a dermatology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PY30 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Galderma Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 20.60 |
| 52 Week High | CHF 20.60 |
| 52 Week Low | CHF 15.30 |
| Beta | 0 |
| 1 Month Change | 15.08% |
| 3 Month Change | 30.38% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 32.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| PY30 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.0% | -0.2% | -0.4% |
| 1Y | n/a | -17.1% | 7.9% |
Return vs Industry: Insufficient data to determine how PY30 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how PY30 performed against the German Market.
Price Volatility
| PY30 volatility | |
|---|---|
| PY30 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PY30 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine PY30's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 6,545 | Flemming Ornskov | www.galderma.com |
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology.
Galderma Group AG Fundamentals Summary
| PY30 fundamental statistics | |
|---|---|
| Market cap | €25.87b |
| Earnings (TTM) | -€13.78m |
| Revenue (TTM) | €4.19b |
6.2x
P/S Ratio-1,877x
P/E RatioIs PY30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PY30 income statement (TTM) | |
|---|---|
| Revenue | US$4.32b |
| Cost of Revenue | US$1.31b |
| Gross Profit | US$3.00b |
| Other Expenses | US$3.02b |
| Earnings | -US$14.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 06, 2025
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 69.54% |
| Net Profit Margin | -0.33% |
| Debt/Equity Ratio | 37.1% |
How did PY30 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 07:24 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Galderma Group AG is covered by 12 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bethan Davies | Berenberg |
| Richard Parkes | BNP Paribas Exane |
| Joffrey Meller | BofA Global Research |